Abstract #0981

High Resolution Pre-Clinical MRI in Murine Braf-Induced Thyroid Tumor Targeted Therapy

Aime T. Franco¹, Ronald A. Ghossein², H. Carl Le³, Jason A. Koutcher,⁴, Jame Fagin⁵

¹Medicine & Human Human Oncology & Pathogenesis Program, MSKCC, New York, NY, United States; ²Pathology, MSKCC, New York, NY, United States; ³Medical Physics, MSKCC, New York, NY, United States; ⁴Medicine, MSKCC; ⁵Medicine & Human Oncology & Pathogenesis Program, MSKCC

We have developed mice with a thyroid-specific knock-in of oncogenic BRAF (LSL-BRAFV600E/TPO-Cre) to explore the role of pharmacological treatments in a physiologically relevant mouse model of PTC. Murine Braf-induced PTCs were treated with the specific allosteric MEK1/2 inhibitor PD325901 or rapamycin for three weeks, beginning at 3 weeks. We have used non-invasively measured thyroid volume by high resolution MRI as the tumor biomarker